Compare iShares US Aerospace & Defense ETF (ITA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares US Aerospace & Defense ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares US Aerospace & Defense ETF trades at $204.16 (market cap $11.96B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares US Aerospace & Defense ETF is far larger — about 2.5× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares US Aerospace & Defense ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Aerospace & Defense ETF for 24 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ITA | TVTX | |
|---|---|---|
Market Cap | $11.96B | $4.88B |
Volume | 750,577 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $253.22 | $67.52 |
52-Week Low | $198.23 | $26.79 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITA trades at $204.00, down 0.99% with bearish technical signals from moving averages. The ETF shows neutral oscillators but faces selling pressure with RSI at oversold levels. Recent corporate actions include a 1:3 stock split scheduled for November 2026 and a $0.25 dividend payment in September 2026. Defense sector momentum remains strong with multiple contract wins and geopolitical tensions driving demand.
The defense sector outlook appears favorable with increased government spending and geopolitical tensions, though ITA faces technical headwinds. Key risks include defense budget volatility and geopolitical resolution. Analyst sentiment remains mixed with the ETF positioned to benefit from ongoing military modernization programs and replenishment of defense inventories.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares US Aerospace & Defense ETF
iShares U.S. Aerospace & Defense ETF seeks to track U.S. companies in the aerospace and defense sector. Its holdings include manufacturers of commercial and military aircraft, defense systems, and related equipment.
Read more on ITA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
